Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Coronary heart disease (CHD) mortality rates have been decreasing in Iceland since the 1980s. We examined how much of the decrease between 1981 and 2006 could be attributed to medical and surgical treatments and how much to changes in cardiovascular risk factors. METHODOLOGY: The previously validated IMPACT CHD mortality model was applied to the Icelandic population. The data sources were official statistics, national quality registers, published trials and meta-analyses, clinical audits and a series of national population surveys. PRINCIPAL FINDINGS: Between 1981 and 2006, CHD mortality rates in Iceland decreased by 80% in men and women aged 25 to 74 years, which resulted in 295 fewer deaths in 2006 than if the 1981 rates had persisted. Incidence of myocardial infarction (MI) decreased by 66% and resulted in some 500 fewer incident MI cases per year, which is a major determinant of possible deaths from MI. Based on the IMPACT model approximately 73% (lower and upper bound estimates: 54%-93%) of the mortality decrease was attributable to risk factor reductions: cholesterol 32%; smoking 22%; systolic blood pressure 22%, and physical inactivity 5% with adverse trends for diabetes (-5%), and obesity (-4%). Approximately 25% (lower and upper bound estimates: 8%-40%) of the mortality decrease was attributable to treatments in individuals: secondary prevention 8%; heart failure treatments 6%; acute coronary syndrome treatments 5%; revascularisation 3%; hypertension treatments 2%, and statins 0.5%. CONCLUSIONS: Almost three quarters of the large CHD mortality decrease in Iceland between 1981 and 2006 was attributable to reductions in major cardiovascular risk factors in the population. These findings emphasize the value of a comprehensive prevention strategy that promotes tobacco control and a healthier diet to reduce incidence of MI and highlights the potential importance of effective, evidence based medical treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More than half of the reduction in CV mortality in the last three decades has been attributed to population-level changes in CV risk factors, primarily reductions in cholesterol and blood pressure levels and smoking. 13-16”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This favourable trend is partly offset by increases in other major risk factors, such as obesity and type 2 diabetes. 13-16”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699 · cited 1×
“The contribution from revascularizations was modest, reflecting a relatively small number of eligible patients and limited mortality benefits in stable angina[25].”
BackgroundExplaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Self-citationOptimal Diets for Prevention of Coronary Heart Disease
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.288.20.2569 · Cited by 1,503 · cited 1×
“meat and dairy products) and (‘‘very bad’’) transfats from hydrogenated fatty acids concealed in junk food, processed food, cakes and cookies.[31]”
BackgroundCritchley, J. A., & Capewell, S. (2003) · JAMA · doi:10.1001/jama.290.1.86 · Cited by 1,089 · cited 1×
“[6,24,25] Sensitivity Analyses Because of the uncertainties surrounding many of the values, multi-way sensitivity analyses were performed using Brigg’s analysis of extremes method.”
MethodSelf-citationUnal, B., Critchley, J. A., & Capewell, S. (2004) · Circulation · doi:10.1161/01.cir.0000118498.35499.b2 · Cited by 739 · cited 5×
“[23] The number of deaths prevented or postponed as a result of the change observed in Iceland was then estimated as:[6] Number of deaths prevented = (12e x change) ) x expected deaths in 2006 = (12e (20.”
BackgroundMethodInfluentialSelf-citationEffect of PCI on Quality of Life in Patients with Stable Coronary Disease
Weintraub, W. S., Spertus, J. A., Kolm, P., Maron, D. J., Zhang, Z., Jurkovitz, C., Zhang, W., Hartigan, P. M., Lewis, C., Veledar, E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072771 · Cited by 727 · cited 1×
“However, the improvement in quality of life is important and well recognized [28].”
BackgroundRepresentation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials
Heiat, A., Gross, C. P., & Krumholz, H. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1682 · Cited by 723 · cited 1×
“Elderly patients and women have been consistently underrepresented in a majority of clinical trials and surveys in cardiovascular disease[35].”
BackgroundHunink, M. G. M. (1997) · JAMA · doi:10.1001/jama.277.7.535 · Cited by 679
Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis
Briggs, A., Sculpher, M., & Buxton, M. (1994) · Health Economics · doi:10.1002/hec.4730030206 · Cited by 521 · cited 1×
“Because of the uncertainties surrounding many of the values, multi-way sensitivity analyses were performed using Brigg’s analysis of extremes method.[26].”
MethodChanges in risk factors explain changes in mortality from ischaemic heart disease in Finland
Vartiainen, E., Puska, P., Pekkanen, J., Toumilehto, J., & Jousilahti, P. (1994) · BMJ · doi:10.1136/bmj.309.6946.23 · Cited by 438 · cited 1×
“[16,17] Results using the IMPACT model were generally consistent with other studies using diverse methodologies in different countries.[18,19,20,21]”
ResultExplaining the Decline in Coronary Heart Disease Mortality in Finland between 1982 and 1997
Laatikainen, T., Critchley, J., Vartiainen, E., Salomaa, V., Ketonen, M., & Capewell, S. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi274 · Cited by 331 · cited 1×
“[4,5,6,7,8,9,10] It was also used to assess substantial increases recently seen in China.”
BackgroundSelf-citationCapewell, S., Morrison, C. E., & McMurray, J. J. (1999) · Heart · doi:10.1136/hrt.81.4.380 · Cited by 308
Self-citationExplaining the Increase in Coronary Heart Disease Mortality in Beijing Between 1984 and 1999
Critchley, J., Liu, J., Zhao, D., Wei, W., & Capewell, S. (2004) · Circulation · doi:10.1161/01.cir.0000140668.91896.ae · Cited by 304
Self-citationMant, J., & Hicks, N. (1995) · BMJ · doi:10.1136/bmj.311.7008.793 · Cited by 303 · cited 1×
“[6] The potential effect of multiple treatments in an individual patient was estimated using the Mant and Hicks cumulative relative benefit approach [22]: Relative Benefit = 12[(12Treatment A)6 (12Treatment B)6 NNN 6 (12Treatment N).”
MethodUnal, B., Critchley, J. A., & Capewell, S. (2005) · BMJ · doi:10.1136/bmj.38561.633345.8f · Cited by 293 · cited 1×
“8%) [27], and the USA (2.”
Self-citationModelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002
Björck, L., Rosengren, A., Bennett, K., Lappas, G., & Capewell, S. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn554 · Cited by 264 · cited 1×
“[4,5,6,7,8,9,10] It was also used to assess substantial increases recently seen in China.”
Self-citationCapewell, S., Beaglehole, R., Seddon, M., & McMurray, J. (2000) · Circulation · doi:10.1161/01.cir.102.13.1511 · Cited by 253
Self-citationCapewell, S., Ford, E. S., Croft, J. B., Critchley, J. A., Greenlund, K. J., & Labarthe, D. R. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.08.057885 · Cited by 200
Self-citationExplaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985–2000
Bennett, K., Kabir, Z., Unal, B., Shelley, E., Critchley, J., Perry, I., Feely, J., & Capewell, S. (2006) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2005.038638 · Cited by 133
Self-citationDecline in ischaemic heart disease in Iceland and change in risk factor levels.
Sigfusson, N., Sigvaldason, H., Steingrimsdottir, L., Gudmundsdottir, I. I., Stefansdottir, I., Thorsteinsson, T., & Sigurdsson, G. (1991) · BMJ · doi:10.1136/bmj.302.6789.1371 · Cited by 103 · cited 1×
“The Icelandic Heart Association (IHA) was established in 1966, and in 1967 it began the Reykjavik Study, a prospective population based cardiovascular survey [2] An earlier report from the Reykjavik Study described the increase in mortality in Icelandic men until the late 1970s and then the decrease during 1981 – 1986…”
BackgroundMedical management and the decline in mortality from coronary heart disease.
Beaglehole, R. (1986) · BMJ · doi:10.1136/bmj.292.6512.33 · Cited by 93 · cited 1×
“[16,17] Results using the IMPACT model were generally consistent with other studies using diverse methodologies in different countries.[18,19,20,21]”
ResultÜnal, B., Critchley, J. A., Fidan, D., & Capewell, S. (2005) · American Journal of Public Health · doi:10.2105/ajph.2003.029579 · Cited by 92
Self-citationBots, M. L., & Grobbee, D. E. (1996) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679600300302 · Cited by 75 · cited 1×
“[16,17] Results using the IMPACT model were generally consistent with other studies using diverse methodologies in different countries.[18,19,20,21]”
ResultFidan, D., Unal, B., Critchley, J., & Capewell, S. (2007) · QJM · doi:10.1093/qjmed/hcm020 · Cited by 61
Self-citationBots, M. L., & Grobbee, D. E. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199606000-00002 · Cited by 55
Ünal, B., Critchley, J., & Capewell, S. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.09.015 · Cited by 46 · cited 1×
“[14] The IMPACT model was subsequently used to address policy questions, estimating the additional deaths which could potentially be prevented, either by increasing the uptake of appropriate treatments in eligible patients,[15] or alternatively, by further modest reductions in specific risk factors.[16,17] Results usi…”
ResultSelf-citationLife-years gained from coronary heart disease mortality reduction in Scotland
Critchley, J., Capewell, S., & Ünal, B. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00059-3 · Cited by 43 · cited 1×
“[11] The model was also able to calculate the life-years gained by different interventions [12,13], and to perform cost-effectiveness analyses.”
MethodSelf-citationSalihu, H. M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16791-3 · Cited by 40
Critchley, J. A., & Capewell, S. (2003) · Journal of Epidemiology and Community Health · doi:10.1136/jech.57.4.243 · Cited by 37 · cited 1×
“[14] The IMPACT model was subsequently used to address policy questions, estimating the additional deaths which could potentially be prevented, either by increasing the uptake of appropriate treatments in eligible patients,[15] or alternatively, by further modest reductions in specific risk factors.[16,17] Results usi…”
ResultSelf-citation[Trends in body weight and diabetes in forty years in Iceland].
Þórsson, B., Aspelund, T., Harris, T. B., Launer, L. J., & Gudnason, V. G. (2009) · PubMed · Cited by 27
Self-citationCapewell, S., Ünal, B., Critchley, J., & McMurray, J. J. V. (2006) · Heart · doi:10.1136/hrt.2004.053645 · Cited by 26 · cited 1×
“[14] The IMPACT model was subsequently used to address policy questions, estimating the additional deaths which could potentially be prevented, either by increasing the uptake of appropriate treatments in eligible patients,[15] or alternatively, by further modest reductions in specific risk factors.”
MethodSelf-citationGudnason, V. G., Þórsson, B., Andersen, K. K., & Sigurdsson, G. T. (2008) · Circulation · doi:10.1161/circ.118.suppl_18.s_1080-b · Cited by 1
Self-citation
Research works printed but not linked: 1
- Capewell S Ford E Croft J Critchley J Greenlund K 2008 Cardiovascular Risk Factor Trends in the US Population and Options for Reducing Future Coronary Heart Disease Mortality. WHO Bulletin (in press)
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“More than one-half of the reduction in CV mortality over the last three decades has been attributed to population-level changes in CV risk factors, primarily reductions in plasma cholesterol, BP levels, and smoking.(560) 563,567 Lifestyle changes at the population level may be more cost-effective than lifestyle and dr…”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Decline in Cardiovascular Mortality: Possible Causes and Implications
Mensah, G. A., Wei, G. S., Sorlie, P. D., Fine, L. J., Rosenberg, Y., Kaufmann, P. G., Mussolino, M. E., Hsu, L. L., Addou, E., Engelgau, M. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309115 · Cited by 847
Metadata
- Authors
- Aspelund, T., Gudnason, V., Magnusdottir, B. T., Andersen, K., Sigurdsson, G., Thorsson, B., Steingrimsdottir, L., Critchley, J., Bennett, K., O'Flaherty, M., & Capewell, S.
- Affiliations
- University of Iceland (IS)
- Newcastle University (GB)
- St. James's Hospital (IE)
- University of Liverpool (GB)
- Corresponding author
- Gudnason, Vilmundur
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-11-12
- Volume
- 5
- Issue
- 11
- Pages
- e13957
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2980472
- OpenAlex
- W2163515455
- Cited by
- 106
- References
- 34
- Citations by year
- 2025: 2 · 2023: 3 · 2022: 9 · 2021: 4 · 2020: 1 · 2019: 12 · 2018: 8 · 2017: 8 · 2016: 12 · 2015: 8 · 2014: 7 · 2013: 10 · 2012: 17
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Háskóli Íslands
- Hjartavernd
- Topics
- Health Sciences › Medicine › Epidemiology › Healthcare Systems and Public Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- coronary heart disease mortality, mortality decline, cardiovascular risk factors, myocardial infarction incidence, cholesterol, smoking, blood pressure, physical inactivity, diabetes mellitus, obesity, secondary prevention, statins, revascularization, acute coronary syndrome, heart failure treatment, tobacco control
- MeSH terms
- Adult, Aged, Coronary Disease, Female, Humans, Iceland, Male, Middle Aged, Mortality, Myocardial Infarction, Models, Statistical, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.